.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Argus Health
Harvard Business School
Federal Trade Commission
Deloitte
US Department of Justice
McKesson
Teva
Covington
AstraZeneca

Generated: September 20, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Antiviral compounds
Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s): Guo; Hongyan (Foster City, CA), Kato; Darryl (Foster City, CA), Kirschberg; Thorsten A. (Foster City, CA), Liu; Hongtao (Foster City, CA), Link; John O. (Foster City, CA), Mitchell; Michael L. (Foster City, CA), Parrish; Jay P. (Foster City, CA), Sun; Jianyu (Foster City, CA), Taylor; James (Foster City, CA), Bacon; Elizabeth M. (Foster City, CA), Canales; Eda (Foster City, CA), Cho; Aesop (Foster City, CA), Kim; Choung U. (Foster City, CA), Cottell; Jeromy J. (Foster City, CA), Desai; Manoj C. (Foster City, CA), Halcomb; Randall L. (Foster City, CA), Lazerwith; Scott E. (Foster City, CA), Mackman; Richard L. (Foster City, CA), Pyun; Hyung-Jung (Foster City, CA), Saugier; Joseph H. (Foster City, CA), Trenkle; James D. (Foster City, CA), Tse; Winston C. (Foster City, CA), Watkins; William J. (Foster City, CA), Xu; Lianhong (Foster City, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:12/779,023
Patent Claims: 1. A compound of formula: ##STR01319## wherein: V is alkyl; L is benzimidazolyl; M is a 5-membered heteroaryl ring; A.sup.15 is: ##STR01320## P is selected from: ##STR01321## ##STR01322## and R''' is hydrogen or methyl; or a pharmaceutically acceptable salt, or prodrug thereof.

2. The compound of claim 1 that is: ##STR01323## or a pharmaceutically acceptable salt, or prodrug thereof.

3. The compound of claim 1 that is: ##STR01324## or a pharmaceutically acceptable salt, or prodrug thereof.

4. The compound of claim 1 wherein P is selected from: ##STR01325##

5. The compound of claim 1 wherein P is ##STR01326##

6. The compound of claim 1 wherein P is ##STR01327##

7. The compound of claim 1 that is: ##STR01328## or a pharmaceutically acceptable salt, or prodrug thereof.

8. The compound of claim 1 that is: ##STR01329## or a pharmaceutically acceptable salt, or prodrug thereof.

9. A compound: ##STR01330## wherein: V is alkyl; M is a 5-membered heteroaryl ring; and A.sup.15 is: ##STR01331## or a pharmaceutically acceptable salt, or prodrug thereof.

10. A compound: ##STR01332## wherein V is alkyl; and A.sup.15 is: ##STR01333## or a pharmaceutically acceptable salt, or prodrug thereof.

11. The compound of claim 1 wherein each V is: ##STR01334##

12. A compound of formula: ##STR01335## or a pharmaceutically acceptable salt, or prodrug thereof.

13. A pharmaceutical composition comprising the compound as described in claim 1 or a pharmaceutically acceptable salt, or prodrug thereof; and at least one pharmaceutically acceptable carrier.

14. The pharmaceutical composition of claim 13, further comprising at least one additional therapeutic agent.

15. The pharmaceutical composition of claim 14, wherein said additional therapeutic agent is selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.

16. The pharmaceutical composition according to claim 13, further comprising a nucleoside analogue.

17. The pharmaceutical composition according to claim 16, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine.

18. A compound of formula: ##STR01336## or a pharmaceutically acceptable salt, or prodrug thereof.

19. A pharmaceutical composition comprising the compound as described in claim 18 or a pharmaceutically acceptable salt, or prodrug thereof and at least one pharmaceutically acceptable carrier.

20. The pharmaceutical composition of claim 19, further comprising at least one additional therapeutic agent.

21. The pharmaceutical composition of claim 20, wherein said additional therapeutic agent is selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.

22. The pharmaceutical composition according to claim 19, further comprising a nucleoside analogue.

23. The pharmaceutical composition according to claim 22, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Covington
Cipla
Merck
Daiichi Sankyo
Farmers Insurance
US Department of Justice
Dow
Teva
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot